Effects of acute renal failure on the pharmacokinetics of oltipraz in rats

Journal of Pharmaceutical Sciences

Volumn 93, Issue 9, 2004, Pages 2353-2363

  Bae, Soo K ^a   Lee, Shin J ^a   Kim, Jin W ^b   Kim, Young H ^b   Kim, Sang G ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b CJ Corporation   (South Korea)

Author keywords

Oltipraz; Pharmacokinetics; Rats; U ARF

Indexed keywords

OLTIPRAZ; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG PROTEIN BINDING; GASTROINTESTINAL ABSORPTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; RAT;

EID: 4344599127     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20141     Document Type: Article

References (39)

1. Clapper M. 1980. Chemopreventive activity of oltipraz. Pharmacol Ther 78:17-27.
2. Bueding E, Dolan P, Leroy JP. 1982. The anti-schistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol 37:293-303.
3. Primiano T, Egner PA, Sutter TR, Kellof GJ, Roebuds BD, Kensler TW. 1995. Intermittent dosing with oltipraz: Relationship between chemo-prevention of aflatoxin-induced tumorigenesis and induction of glutathione-S-transferases. Cancer Res 55:4319-4324.
4. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG. 2002. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 16:1988-1990.
5. Bae SK, Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. 2001. Determination of a chemopreventive agent, oltipraz, in rat plasma and urine by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 110:133-138.
6. Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. 2001. Stability, blood partition and protein binding of an antifibrotic agent, oltipraz. Res Commun Mol Pathol Pharmacol 109:333-344.
7. Bae SK, Kim EJ, Chung SJ, Kim SG, Lee MG. 2003. Pharmacokinetic interaction between oltipraz and dimethyl-4,4′-dimethoxy-5,6,5′, 6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB) after single intravenous and oral administration to rats. J Pharm Pharmacol 55:1241-1249.
8. Moon YJ, Lee AK, Chung HJ, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, Lee MG. 2003. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 31:776-784.
9. Ahn CY, Kim EJ, Lee I, Kwon JW, Kim WB, Kim SG, Lee MG. 2003. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced uranyl nitrate. J Pharm Sci 92:1604-1609.
10. Chung W-S, Kim EJ, Lee I, Kim SG, Lee MG, Kim SH. 2003. Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sci 73:253-263.
11. Cho MK, Kim YG, Lee MG, Kim SG. 1999. Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: Complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 372:150-158.
12. Rockich K, Blouin R. 1999. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077.
13. Lowry OH, Rosebrough NG, Farr AL, Randall RJ. 1951. Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
14. Lineweaver H, Burk D. 1934. The determination of enzyme dissociation constants. J Am Chem Soc 56:658-666.
15. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
16. Yoon WH, Yoo JK, Lee JW, Shim C-K, Lee MG. 1998. Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7, after intravenous and oral administration to rats, rabbits, and dogs. Drug Metab Dispos 26:152-163.
17. Chiou WL, Nation RL, Peng GW, Huang SM. 1978. Improved micro-scale high-pressure liquid-chromatographic assay of gentamicin in plasma. Clin Chem 24:1846-1847.
18. Christensen RG, Malone W. 1992. Determination of oltipraz in serum by high-performance liquid chromatography with optical absorbance and mass spectrometric detection. J Chromatogr 584:207-212.
19. Chiou WL. 1978. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-546.
20. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, Inc.
21. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to rational dosage regimens. J Pharm Sci 69:90-91.
22. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
23. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68:1067-1069.
24. Yu SY, Chung HJ, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. 2002. Effects of acute failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. J Pharm Phamacol 54:1687-1692.
25. Bieder A, Decouvelaere B, Gaillard C, Depaire H, Heusse D, Ledoux C, Lemar M, Leroy JP, Raynaud L, Snozzi C, Gregoire J. 1983. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneim-Forsch/Drug Res 33:1289-1297.
26. Kim YG, Yoon EJ, Yoon WH, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG. 1996. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharm Drug Dispos 17:183-195.
27. Kim HJ, Han KS, Chung Y-K, Chang MS, Lee MG. 1998a. Pharmacokinetic changes of a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol 102:43-56.
28. Kim SH, Shim HJ, Kim WB, Lee MG. 1998b. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob Agents Chemother 42:1217-1221.
29. Son IJ, Moon YG, Lee MG, Sohn YT. 2000. Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol 108:359-368.
30. Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
31. Katayama H, Fujiwara J, Yasuhara M, Okumura K, Hori R. 1984. Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. J Pharmacobiodyn 7:536-544.
32. Park KJ, Kim WH, Shin SH, Lee MG. 1998. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharm Drug Dispos 19:141-146.
33. Itoch T, Sawada Y, Lin H, Iga T, Hanano M. 1988. Kinetic analysis of phenytoin disposition in rats with experimental renal and hepatic disease. J Pharmacobiodyn 11:289-308.
34. Lee YH, Park KH, Ku YS. 2000. Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. Int J Pharm 194:222-227.
35. Lee Y-H, Shim M-H, Shim C-K. 1992. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharm Res 9:1599-1606.
36. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
37. Mitruka BM, Rawnsley HM. 1981. Clinical biochemical and hematological reference values in normal experimental animals and normal humans, 2nd ed. New York: Masson Publishing USA Inc.
38. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
39. Matzke GR, Millikin SP. 1992. Influence of renal function and dialysis on the drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics Inc., pp 8-10.